Affimed N.V.. (1/4/19). "Press Release: Affimed to Present at the 37th Annual J.P. Morgan Healthcare Conference". Heidelberg.

	Region	San Francisco, CA
	Country	United States (USA)
	Organisation	Affimed N.V. (Nasdaq: AFMD)
	Group	Affimed (Group)
	Organisation 2	J.P. Morgan Securities LLC
	Group	JPMorgan Chase (Group)
	Product	J.P. Morgan 37th Annual Healthcare Conference 2019 San Francisco
	Product 2	cancer immunotherapy (immuno-oncology, I-O)
	Index term	Affimed–JPMorgan Chase: investor conference, 201901 supply service Affimed presents at JP Morgan Healthcare Conference 2019
	Person	Hoess, Adi (Affimed 201109– CEO before CCO before Jenowis + Jerini 2003– + Carl Zeiss AG + MorphoSys AG)
	Person 2	Gin, Gregory (Affimed 201808 Head of Investor Relations)

Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to improving patient outcomes through the power of the innate immune system, today announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 11:30 a.m. Pacific Time / 2:30 p.m. Eastern Time.

A live webcast of the presentation can be accessed under the “News & Events” section of Affimed’s website at https://www.affimed.com/investors/webcasts/ and will be available for 30 days following the event.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical stage biopharmaceutical company which engineers targeted immunotherapies, seeking to improve patient outcomes through the power of innate immunity. Affimed’s fit-for-purpose ROCK® platform allows innate immune engagers to be designed for specific patient populations. We are developing single and combination therapies to treat cancers. For more information, please visit www.affimed.com.

Affimed Investor Contact:

Gregory Gin,
Head of Investor Relations
E-Mail: IR@affimed.com

Affimed Media Contact:

Anca Alexandru,
Head of Communications, EU IR
E-Mail: media@affimed.com

Record changed: 2023-06-05